Mycophenolate Mofetil 500mg film-coated tablets Malta - English - Medicines Authority

mycophenolate mofetil 500mg film-coated tablets

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mycophenolate mofetil - film-coated tablet - mycophenolate mofetil 500 mg - immunosuppressants

Mycophenolate Mofetil 250mg Capsules Malta - English - Medicines Authority

mycophenolate mofetil 250mg capsules

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mycophenolate mofetil - hard capsule - mycophenolate mofetil 250 mg - immunosuppressants

Mycophenolate mofetil 500mg powder for concentrate for solution for infusion Malta - English - Medicines Authority

mycophenolate mofetil 500mg powder for concentrate for solution for infusion

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mycophenolate mofetil - powder for concentrate for solution for infusion - mycophenolate mofetil 500 mg - immunosuppressants

DARUNAVIR JUNO darunavir 800 mg film coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

darunavir juno darunavir 800 mg film coated tablet bottle

juno pharmaceuticals pty ltd - darunavir, quantity: 800 mg - tablet, film coated - excipient ingredients: silicified microcrystalline cellulose; macrogol 4000; sodium chloride; iron oxide red; purified talc; titanium dioxide; hyprolose; crospovidone; polacrilin potassium; magnesium stearate; colloidal anhydrous silica; polyvinyl alcohol - adult patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

DARUNAVIR JUNO darunavir 600 mg film coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

darunavir juno darunavir 600 mg film coated tablet bottle

juno pharmaceuticals pty ltd - darunavir, quantity: 600 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; purified talc; polyvinyl alcohol; hyprolose; polacrilin potassium; macrogol 4000; sodium chloride; titanium dioxide; iron oxide red; silicified microcrystalline cellulose; colloidal anhydrous silica; iron oxide yellow - adult patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

DARUNAVIR JUNO darunavir 400 mg film coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

darunavir juno darunavir 400 mg film coated tablet bottle

juno pharmaceuticals pty ltd - darunavir, quantity: 400 mg - tablet, film coated - excipient ingredients: sodium chloride; hyprolose; macrogol 4000; titanium dioxide; crospovidone; polacrilin potassium; iron oxide red; colloidal anhydrous silica; iron oxide yellow; purified talc; silicified microcrystalline cellulose; polyvinyl alcohol; magnesium stearate - adult patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.